Kestra Investment Management LLC Has $773,000 Position in Cencora, Inc. (NYSE:COR)

Kestra Investment Management LLC increased its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 46.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,441 shares of the company's stock after buying an additional 1,087 shares during the period. Kestra Investment Management LLC's holdings in Cencora were worth $773,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in COR. JFS Wealth Advisors LLC increased its stake in shares of Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after buying an additional 46 shares during the last quarter. Concord Wealth Partners bought a new stake in shares of Cencora in the third quarter worth $30,000. Householder Group Estate & Retirement Specialist LLC lifted its position in shares of Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after purchasing an additional 69 shares during the last quarter. Kentucky Trust Co bought a new position in shares of Cencora during the fourth quarter worth about $33,000. Finally, WASHINGTON TRUST Co lifted its position in shares of Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after purchasing an additional 46 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Wall Street Analysts Forecast Growth

COR has been the subject of a number of research analyst reports. Robert W. Baird boosted their price target on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. UBS Group increased their price objective on Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Mizuho began coverage on Cencora in a report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price objective for the company. Evercore ISI lifted their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Finally, Barclays boosted their price objective on Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, Cencora presently has a consensus rating of "Moderate Buy" and a consensus price target of $277.90.

Cencora Stock Performance

Cencora stock traded down $1.99 during trading hours on Friday, hitting $241.47. The stock had a trading volume of 1,060,827 shares, compared to its average volume of 1,488,495. The company has a 50-day moving average of $239.34 and a two-hundred day moving average of $237.46. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The company has a market cap of $46.83 billion, a PE ratio of 34.35, a price-to-earnings-growth ratio of 1.32 and a beta of 0.49. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $262.26.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.91%. The ex-dividend date of this dividend is Friday, February 14th. Cencora's dividend payout ratio is 31.29%.

Insider Activity at Cencora

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares of the company's stock, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.80% of the stock is owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.